Medical & Wellness

Executive Summary For decades, neuropsychiatry was a field characterized by high failure rates and incremental progress, making it a challenging...

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - Strategic Partnership...

Valeo Pharma financial results have showcased a promising trajectory with a reported 3% increase in revenues for the three months...

- 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just...

Minimal residual disease (MRD) assessment has emerged as a game-changing biomarker in the multiple myeloma (MM) treatment landscape. Over the...

Boston Pharmaceuticals' next-generation, long-acting FGF21 analog, efimosfermin alfa (BOS-580), has demonstrated positive results in a Phase 2 trial for metabolic...

- Company to host conference call and webcast at 8:00 a.m. ET on Monday, November 18, 2024 - - Presentation will also include discussion...

- PARADIGM ™ program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) - - APPROACH ™ : A P hase...

Gilead Sciences is implementing a strategic restructuring, including workforce reductions at its Kite Pharma subsidiary and the closure of its...

Fresh off the successful $1.25 billion acquisition of Yellow Jersey Therapeutics by Johnson & Johnson, Kaken Pharmaceutical and Numab Therapeutics...